IMMUNIC, INC. (IMUX) - Dilution Analysis

10-Q filing | 13.6M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 120,284,724 → 12,028,472

S-3 filing: This prospectus relates to the resale by the selling stockholders identified in this prospectus of up to 458,152,000 shares of our common stock.

10-Q filing | 120.3M shares outstanding

10-Q filing | 98.7M shares outstanding

8-K filing: Immunic, Inc. entered into an underwriting agreement for the offering, issuance, and sale of pre-funded warrants and accompanying series A and B warrants to purchase shares of common stock, with expected gross proceeds of approximately $65 million. ($65.0M proceeds)

10-Q filing | 101.3M shares outstanding

8-K filing: Immunic, Inc. entered into a securities purchase agreement to issue and sell 5,666,667 shares of common stock at $0.90 per share, with gross proceeds of approximately $5.1 million, and also agreed to issue warrants to the placement agent to purchase up to 283,334 shares of common stock at an exercise price of $1.125 per share. ($5.1M proceeds)

10-K filing | 90.2M shares outstanding

10-Q filing | 90.1M shares outstanding

10-Q filing | 90.1M shares outstanding

S-3/A filing: The filing is for a shelf offering of common stock, preferred stock, debt securities, warrants, and/or units, up to an aggregate amount of $412,299,419.

10-Q filing | 97.3M shares outstanding

S-3/A filing: This is an S-3/A filing, concerning the potential sale of common stock by a selling stockholder, who may also engage in hedging transactions with broker-dealers in connection with distributions of common stock. The selling stockholder may also sell securities short and redeliver securities to close out such short positions.

10-K filing | 89.9M shares outstanding

S-3 filing: This S-3 filing indicates a shelf registration for the potential future sale of common stock by a selling stockholder. The specific terms, including the number of shares and price, will be detailed in a future prospectus supplement.

S-3 filing: The company is filing an S-3 to register an aggregate of $250,000,000 of various securities and $163,100,000 of unsold securities previously registered under the Registrant's prior registration statement.

10-Q filing | 44.6M shares outstanding

10-Q filing | 44.4M shares outstanding

10-Q filing | 43.7M shares outstanding

10-K filing | 44.4M shares outstanding

S-3 filing: This is an S-3 filing related to the registration of shares of common stock for sale by selling stockholders, from which the company will not receive any proceeds.

10-Q filing | 39.3M shares outstanding

8-K filing: Immunic, Inc. entered into a Securities Purchase Agreement for a private placement to sell 8,696,552 shares of common stock at $4.35 per share and 5,096,552 pre-funded warrants at $4.34 per warrant. ($59.94M proceeds)

10-Q filing | 30.2M shares outstanding

10-Q filing | 28.1M shares outstanding

8-K filing: Immunic, Inc. awarded Dr. Duane Nash an option to purchase 75,000 shares of the Company's common stock, which will vest monthly commencing on April 10, 2022.

10-K filing | 27.9M shares outstanding

10-Q filing | 26.2M shares outstanding

10-Q filing | 26.2M shares outstanding

8-K filing: Immunic, Inc. closed a public offering of 4,500,000 shares of common stock at $10.00 per share, resulting in net proceeds of approximately $42.0 million after deducting underwriting discounts and commissions and estimated offering expenses. ($45.0M proceeds)

10-Q filing | 21.7M shares outstanding

8-K filing: Immunic, Inc. extended the term of its Executive Chairman Agreement with Duane Nash, MD, JD, MBA, and granted him an option to purchase 90,000 shares of Company common stock.

S-3 filing: This S-3 filing relates to the resale of 581,199 shares of common stock by 4SC AG, which were issued to them on March 31, 2021, in exchange for settling royalty obligations.

10-K filing | 21.2M shares outstanding

S-3 filing: The company is filing an S-3 to offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings.

10-Q filing | 20.7M shares outstanding

8-K filing: Immunic, Inc. closed a public offering of 5,750,000 shares of common stock at $18.00 per share, resulting in net proceeds of approximately $97 million. ($97.0M proceeds)

10-Q filing | 15.0M shares outstanding

8-K filing: Immunic, Inc. completed a public offering of 1,975,000 shares of its common stock at a price of $11.40 per share, resulting in aggregate gross proceeds of approximately $25.0 million. ($25.0M proceeds)

10-Q filing | 12.8M shares outstanding

8-K filing: Immunic, Inc. closed a registered direct offering of 1,764,706 shares of common stock at $8.50 per share, resulting in gross proceeds of $15.0 million. ($15.0M proceeds)

10-K filing | 10.7M shares outstanding